<DOC>
	<DOCNO>NCT00168025</DOCNO>
	<brief_summary>The purpose study demonstrate effect IgPro10 prevention serious bacterial infection patient primary immunodeficiency . As secondary endpoint rate overall infection , tolerability safety IgPro10 study . A part patient participate pharmacokinetic substudy .</brief_summary>
	<brief_title>Efficacy Safety Intravenous Immunoglobulin IgPro10 Patients With Primary Immunodeficiencies ( PID )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Key Patients primary immunodeficiency Patients receive stable IVIG therapy 3 4weekly interval least 6 month Key Newly diagnose PID Allergic reaction immunoglobulins blood product Administration steroid ( daily â‰¥ 0.15 mg prednisone equivalent/kg/day ) immunosuppressive drug Concomitant diseases hypoalbuminemia , proteinlosing enteropathy , kidney disease proteinuria , malignancy lymphoid cell ( e.g . lymphocytic leukemia ) , recent history migraine History cardiac insufficiency ( NYHA III/IV ) , cardiomyopathy , congestive heart failure , severe hypertension</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Immunoglobulin Intravenous</keyword>
	<keyword>Agammaglobulinemia</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Common variable immunodeficiency</keyword>
	<keyword>Immunoglobulin G</keyword>
	<keyword>Children</keyword>
</DOC>